Dendritic Cell-based Genetic Immunization in Mice with a Recombinant Adenovirus Encoding Murine TRP2 Induces Effective Anti-melanoma Immunity

Journal of Gene Medicine

Volumn 1, Issue 6, 1999, Pages 400-406

  Tüting, Thomas ^a   Steitz, Julia ^a   Brück, Jürgen ^a   Gambotto, Andrea ^b   Steinbrink, Kerstin ^a   DeLeo, Albert B ^c   Robbins, Paul ^b   Knop, Jürgen ^a   Enk, Alexander H ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Dendritic cells; Genetic immunization; Melanoma; Recombinant adenovirus; TRP2

Indexed keywords

ADENOVIRIDAE; MURINAE;

CANCER VACCINE; DOPACHROME ISOMERASE; ISOMERASE; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ADENOVIRUS; ANIMAL; ARTICLE; C57BL MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; DENDRITIC CELL; EXPERIMENTAL MELANOMA; FEMALE; FLOW CYTOMETRY; GENE VECTOR; GENETICS; GRAFT REJECTION; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MOUSE; REPORTER GENE; TRANSPLANTATION; VIROLOGY;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GENES, REPORTER; GENETIC VECTORS; GRAFT REJECTION; IMMUNE TOLERANCE; IMMUNIZATION; IMMUNOTHERAPY, ACTIVE; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION;

EID: 0033222939     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1521-2254(199911/12)1:6<400::aid-jgm68>3.0.co;2-d     Document Type: Article

References (27)

1. Boon T, Van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183: 725-729.
2. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18: 175-182.
3. Condon C, Watkins SC, Celluzzi CM, et al. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996; 2: 1122-1128.
4. Irvine KR, Rao RB, Rosenberg SA, et al. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996; 156: 238-245.
5. Tüting T, Gambotto A, De Leo AB, et al. Induction of tumor antigen-specific immunity using DNA immunization in mice. Cancer Gene Ther 1999; 6: 73-80.
6. Wang RF, Appella E, Kawakami Y, et al. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184: 2207-2216.
7. Castelli C, Tarsini P, Mazzocchi A, et al. Novel HLA-Cw8-restricted T-cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. J Immunol 1999; 162: 1739-1748.
8. Bloom MB, Perry-Lalley D, Robbins PF, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997; 185: 453-459.
9. Carbone FR, Kurts C, Bennett SRM, et al. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol Today 1998; 19: 368-373.
10. Gong J, Chen D, Kashiwaba M, et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci U S A 1998; 95: 6279-6283.
11. Ludewig B, Odermatt B, Landmann S, et al. Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J Exp Med 1998; 188: 1493-1501.
12. Mayordomo JI, Loftus DJ, Sakamoto H, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 183: 1357-1365.
13. Tüting T, DeLeo AB, Lotze MT, et al. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated virla or 'self' antigens induce antitumor immunity in vivo. Eur J Immunol 1997; 27: 2702-2707.
14. Hardy S, Kitamura M, Harris-Stansil T, et al. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997; 71: 1842-1849.
15. Song W, Kong H-L, Carpenter H, et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186: 1247-1256.
16. Gong J, Chen L, Chen D, et al. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther 1997; 4: 1023-1028.
17. Tillman BW, Gruijl TD, Bakker SA, et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol 1999; 162: 6378-6383.
18. Tüting T, Gambotto A, Storkus WJ, et al. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: Studies with the model tumor antigen β-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Ther 1999; 6: 629-636.
19. Hirschowitz EA, Leonard S, Song W, et al. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther 1998; 5: 975-983.
20. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
21. Kaplan JM, Yu Q, Piraino ST, et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 1999; 163: 699-707.
22. Zeh HJ, Perry-Lalley D, Dudley ME, et al. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999; 162: 989-994.
23. + T-cell responses in antitumor immunity. Curr Opin Immunol 1998; 10: 588-594.
24. Toes REM, Ossendorp F, Offringa R, et al. CD4 T-cells and their role in antitumor immune responses. J Exp Med 1999; 189: 753-756.
25. + T-cells in the antitumor immune response. J Exp Med 1998; 188: 2357-2368.
26. Ossendorp F, Mengede E, Camps M, et al. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998; 187: 693-702.
27. + T lymphocytes. Proc Natl Acad Sci U S A 1999; 96: 2982-2987.